Most commonly, AAV capsids are delivered into the body via intravenous injection, but this method has limited success in targeting kidney cells and can sometimes cause harmful side effects ...

For example, using TRACER, Voyager has discovered a series of novel AAV capsids that, following intravenous (IV) administration, achieve up to 1,000-fold higher RNA expression in the brain and 100 ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.